Abstract
Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS that
causes significant disability in young adults. Worldwide, millions of people
are affected by multiple sclerosis. Although there is no cure, approved
treatments are available to slow the progression of MS and offer improved
quality of life.
The market for these treatments has grown 15% since 2004 and continued
double-digit growth is expected in the near term. Kalorama Information' s:
Multiple Sclerosis: A Market Briefing takes a detailed look at multiple
sclerois worldwide and the market for MS treatments, as well as treatments
that will be available in the future. Kalorama' s study focusing on the
following four treatments:
- Copaxone
- Avonex
- Rebif
- Betaseron/Betaferon
As part of its continuing coverage, this report provides:
- Overview of Multiple Sclerosis and its Progression.
- Complete Incidence and Prevalence Statistics For U.S. and Worldwide.
- Triggers and Risk Factors of MS.
- Review of Multiple Sclerosis Treatments on the Market
- Market Size and Forecasts For Treatements to 2011.
- Issues and Trendsfacing MS treatment
- New Multiple Sclerosis Treatments in the pipleline.
As part of Kalorama' s trusted information -gathering process, intensive
research into company, trade and medical literature was supplemented by
interviews with experts in the multiple sclerosis treatment industry.
Interviews make up the source of forecast and market size figures.
The Multiple Sclerosis market is examined for the U.S., European and Japanese
markets.
| 
View Cart
